Symbols / ACIU $3.32 +6.07%

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• AC Immune SA's (NASDAQ:ACIU) stock price dropped 11% last week; retail investors would not be happy - simplywall.st Wed, 10 Dec 2025 08
• AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen - MarketBeat Sat, 28 Feb 2026 08
• ACIU: BTIG Reiterates Buy Rating with $8 Target Price | ACIU Sto - GuruFocus Mon, 16 Mar 2026 11
• Parkinson’s trial hints AC Immune vaccine may slow disease - Stock Titan Fri, 13 Mar 2026 11
• Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026 - Meyka Mon, 16 Mar 2026 08
• Jefferies reiterates AC Immune stock Buy rating on vaccine data - Investing.com Fri, 13 Mar 2026 14
• AC Immune (ACIU) Loss Of CHF 15.9 Million Tests Bullish Profitability Narratives - Sahm Fri, 13 Mar 2026 07
• AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks Fri, 13 Mar 2026 12
• AC Immune surges on positive mid-stage trial data for Parkinson’s drug - Seeking Alpha hu, 11 Dec 2025 08
• Here's Why We're Watching AC Immune's (NASDAQ:ACIU) Cash Burn Situation - Yahoo Finance Fri, 05 Dec 2025 08
• Why Is AC Immune Stock Up Over 23% Today? - Stocktwits hu, 11 Dec 2025 08
• AC Immune (NASDAQ:ACIU) Given Average Recommendation of "Hold" by Brokerages - MarketBeat Fri, 13 Mar 2026 18
• First tests for AC Immune pill targeting brain inflammation in Alzheimer’s - Stock Titan ue, 24 Feb 2026 08
• AC Immune stock rises after positive Parkinson’s disease trial data - Investing.com hu, 11 Dec 2025 08
• BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU) - MarketBeat Mon, 16 Mar 2026 12

• Income Statement
• Balance Sheet
• Cash Flow

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).